223648-39-3

Usage

Type of Compound

Chemical compound

Usage

Organic synthesis and peptide chemistry

Derivative of

L-cyclohexylalanine (an amino acid)

Potential Applications

Pharmaceutical industry

Boc (tert-butoxycarbonyl) Group

Protecting group in peptide synthesis

Function of Boc Group

Protects the amine group and prevents unwanted reactions

Role in Peptide Synthesis

Building block in the creation of peptides and proteins

Design Purpose

Facilitates peptide synthesis by offering protection to the amine group

Selective Deprotection

Allows for further modification of the molecule

Upstream product

• 115951-16-1 1-tert-butoxycarbonylaminocyclohexanecarboxylic acid 

Downstream Products

• 223648-53-1 (S)-2-[(R)-1-(1-Carbamoyl-cyclohexyl)-2-oxo-pyrrolidin-3-ylcarbamoyl]-pyrrolidine-1-carboxylic acid benzyl ester 
• 223648-45-1 [1-(1-carbamoyl-cyclohexylcarbamoyl)-3-methylsulfanyl-propyl]-carbamic acid tert-butyl ester 
• 223648-49-5 [1-(1-carbamoyl-cyclohexyl)-2-oxo-pyrrolidin-3-yl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

A PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND

The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R1 and R2 are the same or different and each an optionally substituted aryl group etc, R0 is hydrogen atom, an alkyl group etc, E is a group of the formula: -C(=O)- or -SO?2#191-, R is a group of the following formula [i], [ii] or [iii] etc: Ring A is (a) a C?3-8#191 cycloalkyl group optionally fused to a benzene ring or (b) a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom etc, R3 is an alkyl group optionally substituted by an alkylthio group, R4 is hydrogen atom, an alkyl group etc, one of RA and RB is an alkyl group etc, and the other is hydrogen atom, an alkyl group etc, or a pharmaceutically acceptable salt thereof.

NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring α,α- disubstituted amino acids

In the present study, L-prolyl-L-leucyl-glycinamide (1) peptidomimetics 3a-3d and 4a-4d were synthesized utilizing α,α-disubstituted amino acids. These analogues were designed to explore the conformational effects of constraints at the φ3 and ψ3 torsion angles. Constrained conformations were verified by the use of X-ray crystallography and circular dichroism. The effects of Pro-Leu-Gly-NH2 analognes 3a-3d and 4a-4d on enhancing rotational behavior induced by apomorphine in the 6-hydroxydopamine-lesioned animal models of Parkinson's disease were studied. The ability of these peptidomimetics to increase the binding of agonist N-propylnorapomorphine (NPA) to the dopamine D2 receptor was also examined. Extended analogue Pro- Leu-Deg-NH2 was the most active compound of this series. It was 10 times more potent and almost 2 times more effective than 1 in increasing apomorphine-induced rotations (56 ± 15% at 1.0 mg/kg ip) and in enhancing [3H]NPA specific binding (40%).